(Q36702091)

15 August 2017

1 reference

title

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

1

Gillian M Keating

1 reference

15 August 2017

Katherine F Croom

2

1 reference

15 August 2017

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

67

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

121-153

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767010-00013

15 August 2017

exact match

0 references

cites work

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767010-00013

Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767010-00013

Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767010-00013

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767010-00013

Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F00003495-200767010-00013

21 January 2018

12 December 2020

European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by i

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767010-00013

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767010-00013

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

12 December 2020

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

1 reference

12 December 2020

Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics

1 reference

12 December 2020

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

12 December 2020

Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone

1 reference

12 December 2020

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

1 reference

12 December 2020

After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?

1 reference

12 December 2020

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

1 reference

12 December 2020

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

1 reference

12 December 2020

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

1 reference

12 December 2020

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate

1 reference

12 December 2020

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

12 December 2020

Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy

1 reference

12 December 2020

Fenofibrate monotherapy induced rhabdomyolysis

1 reference

12 December 2020

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

1 reference

12 December 2020

Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia

1 reference

12 December 2020

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

12 December 2020

Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study

1 reference

12 December 2020

Increasing prevalence of the metabolic syndrome among u.s. Adults.

1 reference

12 December 2020

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

12 December 2020

Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.

1 reference

12 December 2020

Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study

1 reference

12 December 2020

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy

1 reference

12 December 2020

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients

1 reference

12 December 2020

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

1 reference

12 December 2020

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

1 reference

12 December 2020

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

1 reference

12 December 2020

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

1 reference

12 December 2020

Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study

1 reference

12 December 2020

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

1 reference

12 December 2020

Risk of adverse events with fibrates

1 reference

12 December 2020

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia

1 reference

12 December 2020

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

12 December 2020

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

1 reference

12 December 2020

Fenofibrate-induced myopathy

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

1 reference

12 December 2020

ABC of arterial and venous disease: vascular complications of diabetes

1 reference

12 December 2020

Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.

1 reference

12 December 2020

Standards of medical care in diabetes

1 reference

12 December 2020

Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.

1 reference

12 December 2020

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome

1 reference

12 December 2020

Reducing residual risk for patients on statin therapy: the potential role of combination therapy

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

1 reference

12 December 2020

AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis.

1 reference

12 December 2020

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

1 reference

12 December 2020

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

1 reference

12 December 2020

A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.

1 reference

12 December 2020

Lipid-lowering drugs and homocysteine

1 reference

12 December 2020

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

1 reference

12 December 2020

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

1 reference

12 December 2020

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values

1 reference

12 December 2020

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

1 reference

12 December 2020

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

12 December 2020

Effects of fenofibrate and gemfibrozil on plasma homocysteine

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia

1 reference

12 December 2020

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism

1 reference

12 December 2020

Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function

1 reference

12 December 2020

Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia

1 reference

12 December 2020

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

12 December 2020

Management of diabetic dyslipidemia: need for reappraisal of the goals

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy

1 reference

12 December 2020

The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.

1 reference

12 December 2020

Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia

1 reference

12 December 2020

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

1 reference

12 December 2020

Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting

1 reference

12 December 2020

Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia

1 reference

12 December 2020

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

12 December 2020

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

1 reference

12 December 2020

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia

1 reference

12 December 2020

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

1 reference

12 December 2020

Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study

1 reference

12 December 2020

Simvastatin, fenofibrate, and rhabdomyolysis

1 reference

12 December 2020

Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers

1 reference

12 December 2020

Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease

1 reference

12 December 2020

Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study

1 reference

12 December 2020

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome

1 reference

12 December 2020

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

1 reference

12 December 2020

A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?

1 reference

12 December 2020

The role of fibrates in a statin world

1 reference

12 December 2020

Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.

1 reference

12 December 2020

Normalization of metabolic syndrome using fenofibrate, metformin or their combination

1 reference

12 December 2020

Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium

1 reference

12 December 2020

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

12 December 2020

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

12 December 2020

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

1 reference

12 December 2020

Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials

1 reference

12 December 2020

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

1 reference

12 December 2020

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

1 reference

12 December 2020

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

1 reference

12 December 2020

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

1 reference

12 December 2020

The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia

1 reference

12 December 2020

Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks

1 reference

12 December 2020

Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia

1 reference

12 December 2020

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

1 reference

12 December 2020

Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia

1 reference

12 December 2020

Fenofibrate improves microcirculation in patients with hyperlipidemia

1 reference

12 December 2020

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

12 December 2020

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?

1 reference

12 December 2020

Micronised fenofibrate

1 reference

12 December 2020

Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects

1 reference

12 December 2020

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

12 December 2020

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

12 December 2020

Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb

1 reference

12 December 2020

Monocyte suppressing action of fenofibrate

1 reference

12 December 2020

Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.

1 reference

12 December 2020

A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate

1 reference

12 December 2020

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

1 reference

12 December 2020

Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia

1 reference

12 December 2020

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

12 December 2020

A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism

1 reference

12 December 2020

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

1 reference

12 December 2020

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

1 reference

12 December 2020

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

1 reference

12 December 2020

Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.

1 reference

12 December 2020

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action

1 reference

12 December 2020

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

1 reference

12 December 2020

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

1 reference

12 December 2020

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

1 reference

12 December 2020

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

12 December 2020

Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

1 reference

12 December 2020

Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency

1 reference

12 December 2020

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

12 December 2020

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

1 reference

12 December 2020

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

1 reference

12 December 2020

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

1 reference

12 December 2020

Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Peroxisome proliferator-activated receptors, orphans with ligands and functions

1 reference

12 December 2020

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

12 December 2020

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

1 reference

12 December 2020

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

12 December 2020

Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).

1 reference

12 December 2020

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

1 reference

12 December 2020

Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia

1 reference

12 December 2020

Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients

1 reference

12 December 2020

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia

1 reference

12 December 2020

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

10.2165/00003495-200767010-00013

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1004708025

0 references

1 reference